Find information on thousands of medical conditions and prescription drugs.

Lovenox

In medicine, low molecular weight heparin (LMWH) is a class of medication used as an anticoagulant in diseases that feature thrombosis, as well as for prophylaxis in situations that lead to a high risk of thrombosis. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Heparin is a naturally-occurring polysaccharide that inhibits coagulation, the process whereby thrombosis occurs. In nature, heparin consists of molecular chains of varying lengths, or molecular weights. Heparin derived from natural sources (including intestine) can be administered therapeutically to prevent thrombosis (see anticoagulation). However, the effects of natural, or unfractionated, heparin can be difficult to predict. After a standard dose of unfractionated heparin, coagulation parameters must be monitored very closely to prevent over- or under-anticoagulation.

Low molecular weight heparin, in contrast, consists of only short chains of polysaccharide, obtained by the deaminative hydrolysis of unfractionated heparin. Nitrous acid selectively cleaves the glycosidic bonds of the heparin with formation of di, tetra, hexa and higher saccharides terminated with 2,5-anhydro-D-mannose (AM) residues as reducing terminal groups. Having a lower average molecular weight means that a given dose of LMWH will be absorbed more predictably, leading to overall more predictable anticoagulation. It is also more selective for factor Xa and has less effect on thrombin.

Its differences with unfractioned heparin are:

  • Average molecular weight: heparin is about 20000 Da and LMWH is about 3000 Da
  • No need for monitoring of the APTT coagulation parameter
  • Possibly a smaller risk of bleeding
  • Smaller risk of osteoporosis in long-time use
  • Smaller risk of heparin-induced thrombocytopenia, a feared side-effect of heparin.

Because it can be given subcutaneously and does not require aPTT monitoring, LMWH permits outpatient treatment of conditions such as deep vein thrombosis or pulmonary embolism that previously mandated inpatient hospitalization for unfractionated heparin administration

The use of LMWH needs to be monitored closely in patients at extremes of weight or in patients with renal dysfunction. An anti-factor Xa activity may be useful for monitoring anticoagulation. Given its renal clearance, LMWH may not be feasible in patients who have end stage renal disease.

Makes of LMWHs include:

  • Bemiparin (Zibor®)
  • Dalteparin (Fragmin®)
  • Enoxaparin (Clexane® and Lovenox®)
  • Nadroparin (Fraxiparin® and Fraxodi®)
  • Tinzaparin (Innohep®)
  • Several others

Reference

  • Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98. PMID 9278467.

Read more at Wikipedia.org


[List your site here Free!]


Lovenox pregnancy warning proves controversial - Congenital Anomalies at Issue
From OB/GYN News, 6/15/02 by Kate Johnson

Recently issued precautions about congenital anomalies associated with Lovenox use in pregnancy should not dissuade doctors from prescribing the drug, but they should heed the warning not to use it in women with prosthetic heart valves, according to one expert.

Aventis, which manufactures the low-molecular-weight heparin (LMWH), sent a letter to health care professionals in February about additions to the drug's labeling information. According to the letter, congenital anomalies reported in infants born to women who received the drug during pregnancy include cerebral anomalies, limb anomalies, hypospadias, peripheral vascular malformations, fibrotic dysplasia, and cardiac defects. It also noted that a cause-and-effect relationship has not been established and that the incidence of these defects was no higher than in the general population.

The revised label also includes a warning that Lovenox (enoxaparin) is not recommended for use in patients with prosthetic heart valves because of an increased risk of valvular thrombosis.

But according to Dr. Charles Lockwood, the revised label should not prevent physicians from using the drug in most pregnant women. "There is no reason to change practice in any way except to avoid low molecular weight heparin in women with mechanical prosthetic heart valves," said Dr. Lockwood, professor and chair of obstetrics and gynecology at New York University, New York.

"The agent does not cross the placenta, providing no biological plausibility for such a risk. Secondly, a large study by Dr. J. Lepercq and associates [BJOG 108(1l):1134-40, 2001] described pregnancy outcomes in 604 women treated with enoxaparin and observed a congenital anomaly rate of only 2.5%. And lastly, the variety of anomalies reported by Aventis and their rare occurrence strongly suggests no specific malformation pattern or increased frequency," he said.

The American College of Obstetricians and Gynecologists has yet to issue an official position on use of LMWH in pregnancy and congenital defects but is considering the matter in detail, said Dr. Lockwood, chair of ACOG's Committee on Obstetric Practice.

A spokeswoman for Aventis in Bridgewater, N.J., said that the label revision was meant as "a precaution" and that the company is currently "in discussions to perhaps revisit the warning" and that "it might be toned down."

In the meantime, the revised label creates a "tremendous dilemma" for practitioners, said Dr. Philip Blatt, chief of hematology at Christiana Hospital in Newark, Del.

Pregnant women who need LMWH for either current or prior blood clots, recurrent miscarriage, or antiphospholipidantibody syndrome have few alternatives for treatment. "Coumadin [warfarin] is something we try not to use in pregnant women, and the advantages of low-molecular-weight heparin over standard heparin are significant. Some institutions have decided to use standard heparin in the first trimester and then switch back to LMWH. Whether this is an appropriate approach I don't know," Dr. Blatt said.

The advantages of LMWH over standard heparin, he said, are a 10-fold decreased risk of thrombocytopenia, a decreased risk of osteopenia, and much easier monitoring.

"Figuring out an appropriate dose is much more difficult with standard heparin than it is with LMWH," Dr. Blatt said.

"It has to be monitored and it's variable; those of us who did it a lot know it wasn't easy. If this turns out that this is what's required, I think that would be a big disappointment," he added.

There are two other low-molecular-weight heparins approved in the United States, dalteparin (Fragmin, manufactured by Pharmacia) and tinzaparin (Innohep, manufactured by DuPont Pharma Inc.). Spokespeople for both companies say there is no revised labeling for either product.

Labels on both agents say there are no adequate, well-controlled studies of the drug in pregnant women and that it should be used in pregnancy only "if clearly needed."

In addition, the Innohep label says "There has been one case each reported of deft palate, optic nerve hypoplasia, and trisomy 21 [Down] syndrome in infants of women who received Innohep ... during pregnancy. A cause and effect relationship has not been established."

The label also states that there have been four reports of fetal death/miscarriage in pregnant women receiving Innohep who had high-risk pregnancies and/or a history of spontaneous abortion. Approximately 6% of pregnancies were complicated by fetal distress. There have been spontaneous reports of one case each of pulmonary hypoplasia or muscular hypotonia in infants of women receiving Innohep during pregnancy. A cause-and-effect relationship has not been established.

COPYRIGHT 2002 International Medical News Group
COPYRIGHT 2002 Gale Group

Return to Lovenox
Home Contact Resources Exchange Links ebay